CARLSBAD, Calif.--(BUSINESS WIRE)--The bioproduction industry now has access to a new serum replacement for immune cell culture that helps minimize supply and safety risks that have been persistent problems for development of cell therapeutics. The GIBCO CTS Immune Cell SR can be used with many base media in less time, with lower costs and with greater consistency than traditional sera to support a wide range of immune cells, including CAR T cells.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
